182 related articles for article (PubMed ID: 36562471)
1. Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation.
Adhikary G; Shrestha S; Naselsky W; Newland JJ; Chen X; Xu W; Emadi A; Friedberg JS; Eckert RL
Mol Carcinog; 2023 Apr; 62(4):438-449. PubMed ID: 36562471
[TBL] [Abstract][Full Text] [Related]
2. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
[TBL] [Abstract][Full Text] [Related]
3. The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.
Kandasamy S; Adhikary G; Rorke EA; Friedberg JS; Mickle MB; Alexander HR; Eckert RL
Mol Cancer Res; 2020 Mar; 18(3):343-351. PubMed ID: 31732616
[TBL] [Abstract][Full Text] [Related]
4. VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype.
Mickle M; Adhikary G; Shrestha S; Xu W; Eckert RL
Mol Carcinog; 2021 Jul; 60(7):497-507. PubMed ID: 34004031
[TBL] [Abstract][Full Text] [Related]
5. TEAD1 (TEA Domain Transcription Factor 1) Promotes Smooth Muscle Cell Proliferation Through Upregulating SLC1A5 (Solute Carrier Family 1 Member 5)-Mediated Glutamine Uptake.
Osman I; He X; Liu J; Dong K; Wen T; Zhang F; Yu L; Hu G; Xin H; Zhang W; Zhou J
Circ Res; 2019 Apr; 124(9):1309-1322. PubMed ID: 30801233
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotype.
Chen X; Adhikary G; Ma E; Newland JJ; Naselsky W; Xu W; Eckert RL
Mol Carcinog; 2023 Feb; 62(2):236-248. PubMed ID: 36285644
[TBL] [Abstract][Full Text] [Related]
7. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
8. YAP1 is essential for malignant mesothelioma tumor maintenance.
Calvet L; Dos-Santos O; Spanakis E; Jean-Baptiste V; Le Bail JC; Buzy A; Paul P; Henry C; Valence S; Dib C; Pollard J; Sidhu S; Moll J; Debussche L; Valtingojer I
BMC Cancer; 2022 Jun; 22(1):639. PubMed ID: 35689194
[TBL] [Abstract][Full Text] [Related]
9. LncRNA
Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
[TBL] [Abstract][Full Text] [Related]
10. Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling.
Liu Y; Wang S; Pan S; Yan Q; Li Y; Zhao Y
J Clin Lab Anal; 2022 Jan; 36(1):e24116. PubMed ID: 34811815
[TBL] [Abstract][Full Text] [Related]
11. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
Ota M; Sasaki H
Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
[TBL] [Abstract][Full Text] [Related]
12. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
13. Targeting YAP in malignant pleural mesothelioma.
Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
[TBL] [Abstract][Full Text] [Related]
14. Circ_0001273 downregulation inhibits the growth, migration and glutamine metabolism of esophageal cancer cells via targeting the miR-622/SLC1A5 signaling axis.
Wu B; Chen Y; Chen Y; Xie X; Liang H; Peng F; Che W
Thorac Cancer; 2022 Jun; 13(12):1795-1805. PubMed ID: 35567340
[TBL] [Abstract][Full Text] [Related]
15. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
16. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1.
Kandasamy P; Zlobec I; Nydegger DT; Pujol-Giménez J; Bhardwaj R; Shirasawa S; Tsunoda T; Hediger MA
Mol Oncol; 2021 Oct; 15(10):2782-2800. PubMed ID: 34003553
[TBL] [Abstract][Full Text] [Related]
18. Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma.
Kawakami I; Yoshino H; Fukumoto W; Tamai M; Okamura S; Osako Y; Sakaguchi T; Inoguchi S; Matsushita R; Yamada Y; Tatarano S; Nakagawa M; Enokida H
Biochem Biophys Res Commun; 2022 Jun; 611():99-106. PubMed ID: 35487063
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of circular RNA septin 9 inhibits the malignant progression of breast cancer by reducing the expression of solute carrier family 1 member 5 in a microRNA-149-5p-dependent manner.
Wang J; Yang K; Cao J; Li L
Bioengineered; 2021 Dec; 12(2):10624-10637. PubMed ID: 34738502
[TBL] [Abstract][Full Text] [Related]
20. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.
Hassanein M; Hoeksema MD; Shiota M; Qian J; Harris BK; Chen H; Clark JE; Alborn WE; Eisenberg R; Massion PP
Clin Cancer Res; 2013 Feb; 19(3):560-70. PubMed ID: 23213057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
